Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Corey J. Langer, MD

Corey J. Langer, MD Physician

Director, Thoracic Oncology Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Langer is employed by Penn Medicine.

About Dr. Corey J. Langer

Recognized by America's Top Doctors, 2008, 2010 - 2018

Recognized by Best Doctors in America 2009, 2010, 2013 - 2018

Recognized annually in Philadelphia magazine's Top Docs issue, 2009 - 2018

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 1986
  • Internal Medicine, 1984
  • Medical Oncology, 1987

Clinical Expertise:

  • Head and Neck Cancer
  • Lung Cancer

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Boston University School of Medicine
Residency: Graduate Hospital
Fellowship: Penn Presbyterian Medical Center
Fellowship: Fox Chase Cancer Center


American Association for Cancer Research, (Member), National American College of Physicians, National American College of Surgeons Head and Neck Database Committee, National American Society of Clinical Oncology, National BMS Advisory Board on Ipilimumab, National Eastern Cooperative Oncology Group (ECOG), Chair of Aging Subcommittee of the Outcomes Committee, National Geriatric Oncology Consortium (GOC), Member Scientific Advisors Board, National Geriatric Oncology Consortium (GOC), National International Association for Study of Lung Cancer, International Lung Cancer Partnership, Local National Comprehensive Cancer Network Non-Small Cell Lung Cancer Panel, National National Comprehensive Cancer Network Small Cell Lung Cancer Panel, National Oncology Physician Network (OPN), Inc., Philadelphia, Local Ortho Advisory Board, National Pennsylvania Medical Society, Local Pharmacyclics Advisory Board, National Program Committee of the International Association of Lung Cancer, International

Hospital Affiliation

Dr. Langer is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Selected Publications:

Movsas B, Scott C, Curran Jr W, Byardt R and Langer C.: A Quality-Adjusted Time Without Symptoms or Toxicity (QTWiST) Analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol (ASCO), San Francisco, CA, J Clin Oncol, in press. : 2008.

Schnoll RA, James C, Malstrom M, Rothman R, Wang H, Babb J, Miller SM, Ridge JA, Movsas B, Langer C, Unger M, Goldberg M: Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Annals of Behavioral Medicine, in press : 2008.

Langer, CJ Stephenson, P, Schiller J, Harrington D, Sandler A, Belani, C, Johnson D: The Role of Combination Platinum-Based Treatment in the Elderly: Lessons from ECOG 1594 Clinical Lung Cancer, Cancer Conference Highlights, in press : 2008.

Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati, A, Fidias F, Obasaju C, Monberg M, Kindler HA: Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy Naïve Malignant Pleural Mesothelioma J Clin Oncol, in press : 2008.

Konski A; Bhargavan M; Owen J, Komaki R, Langer C, Byhardt R; Paulus R, Choy H, Bruner D, Curran W: Less is not always more; An Economic Analysis of Radiatoin Therapy Oncology Group 9410 Poster 1080, American Society of Therapeutic Radiation Oncology, Los Angeles, CA : 2007.

Movsas B; Moughan J; Sarna L; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Wasserman T; Bruner D; : Quality of Life (QoL) supercedes the classic predictors of survival in locally advanced non-small cel l lung cancer: An analysis of Radiation Therpay Oncology Group (RTOG) 9801 Oral presentation. American Society of Therapeutic Radiation Oncology, Los Angeles, CA : 2007.

Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K: Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol.20;25(30):4800-5 : 2007.

Wakelee HA, Dahlberg SE, Schiller JH, Langer CJ, Sandler AB, Brahmer JR, Belani CP: Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker. Journal of Thoracic Oncology, Vol 2, No 8, Supplement 4, S570, P1-052 : 2007.

Langer CJ, Paulus R, Curran W, Movsas B Werner-Wasik M, Komaki R, Lee JS, Choy H: Rethinking prognostic factors in the era of combined modality therapy for locally advanced non-small cell lung cancer (LA-NSCLC): a retrospective analysis of RTOG Protocols 9410 and 9801. Journal of Thoracic Oncology, Vol 2, No 8, Supplement 4, S309 A1-03 : 2007.

Movsas B, Langer C, Wang LH, Jotte R, Xu F, Huang C, Monberg M, Obasaju CK: Phase 2 trial of cisplatin, etoposide, and radiation followed by gemcitabine vs gemcitabine and docetaxel in stage IIIA/B unresectable non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, Vol 2, No 8, Supplement 4, S648, P2-195 : 2007.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-206
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 615-5121
Patient appointments: 800-789-7366 (PENN)

Related Links